CANY
KPTI icon

Caxton Associates (New York)’s Karyopharm Therapeutics KPTI Stock Holding History

Caxton Associates (New York)’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,708
Closed -$917K – 576
2023
Q1 		$917K Buy
15,708
+10,646
+210% +$526K 0.14% 161
2022
Q4 		$258K Buy
5,062
+268
+6% +$18.6K 0.02% 349
2022
Q3 		$393K Buy
4,794
+1,394
+41% +$104K 0.05% 282
2022
Q2 		$230K Buy
+3,400
New +$312K 0.02% 443

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Caxton Associates (New York)'s KPTI Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 15,708 shares — an estimated $917K sold.

Caxton Associates (New York) first reported a position in KPTI in Q2 2022 and held it in 4 quarters. The position peaked at $917K in Q1 2023. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 15,708 Karyopharm Therapeutics shares in Q2 2023, an estimated $917K.
  • Caxton Associates (New York) first reported a position in Karyopharm Therapeutics in Q2 2022 and held it in 4 quarters.
  • Caxton Associates (New York)'s Karyopharm Therapeutics position peaked at $917K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.